News | August 10, 2021
SMS Pharmaceuticals revenue grows by 44%; Profit up 235%
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
Deal signed with AOP Orphan for US commercial rights
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
The drug is indicated for mild and transient episodes of heart block
Subscribe To Our Newsletter & Stay Updated
